- Home
- BJRI vs XNCR Comparison
BJRI vs XNCR Comparison
Compare BJRI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | XNCR |
|---|---|---|
| Founded | 1978 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.2M | 881.9M |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BJRI | XNCR |
|---|---|---|
| Price | $36.91 | $12.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $44.14 | $22.89 |
| AVG Volume (30 Days) | 314.6K | ★ 481.3K |
| Earning Date | 05-29-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 208.57 | 65.36 |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $3.82 | $6.64 |
| P/E Ratio | $24.15 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $28.46 | $6.92 |
| 52 Week High | $47.02 | $18.69 |
Technical Indicators
Market Signals| Indicator | BJRI | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 28.76 | 48.86 |
| Support Level | $33.45 | $11.02 |
| Resistance Level | $38.56 | $12.58 |
| Average True Range (ATR) | 1.92 | 0.89 |
| MACD | -0.56 | 0.22 |
| Stochastic Oscillator | 2.13 | 33.48 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.